First do no harm? UH prof taking opposite approach to treat asthma

Apr 09, 2008
First do no harm? UH prof taking opposite approach to treat asthma
Richard Bond, associate professor of pharmacology at UH, pictured in his lab with tools he's used in research that takes a new approach to treating asthma by using a concept called "paradoxical pharmacology." Credit: Thomas Shea

One month of tough breathing may help asthma sufferers breathe easier in the long run, according to research from one University of Houston professor.

In a move that challenges one of the most basic tenets of the Hippocratic Oath – first do no harm – Richard Bond, associate professor of pharmacology at UH, is relying on a long-standing medical taboo to treat asthma. Although counterintuitive, Bond’s studies are reminiscent of hair-of-the-dog folk wisdom to treat like with like, in this case using beta blockers (or antagonists) instead of stimulants (or agonists) in asthmatics.

Coining the term “paradoxical pharmacology” – treating patients with medicine that initially worsens their symptoms before eventually improving their overall health – Bond first applied this hypothesis in studies with mice and then moved on to two clinical trials with humans. Currently in the second clinical trial, the part of this research analyzing mice was recently published in the American Journal of Respiratory Cell and Molecular Biology, which cited the relevance of Bond’s work as possibly leading to a paradigm shift in the treatment of asthma. The results of the first human trial were also recently published in Pulmonary Pharmacology and Therapeutics.

Acute asthma attacks have traditionally been treated with inhaler-type stimulant drugs that open constricted airways. Giving beta blockers to asthmatics has long been thought to be contraindicated, because their acute use may cause increased airway resistance. While the use of beta-stimulants is known to provide temporary relief, their effectiveness declines over time.

Bond’s tests initially done on asthmatic mice and later replicated in his first clinical trial with humans showed that while beta blockers initially made breathing problems worse, their continued use resulted in improved respiratory function after a 28-day period. These longer-term effects demonstrate that chronic use of beta blockers alleviates asthma by helping the smooth muscle lining the airways to relax and dilate, thereby allowing air to flow more freely.

“In order to move certain ideas forward, science often needs to be a collaborative effort,” Bond said. “You must find the right people willing to act as a team. I have been very lucky in that people have given my ideas a chance.”

Enlisting the help of some pulmonologists in the Texas Medical Center, Bond collaborated with Dr. Nick Hanania at The Baylor College of Medicine on both human trials. Also, Dr. Burton Dickey, chair of the department of pulmonary medicine at M.D. Anderson Cancer Center, and his colleagues decided to assist Bond’s research efforts when the mouse studies showed that chronic beta-blocker treatment has significant anti-inflammatory effects.

Using beta blockers when it seems a stimulant is called for defies medical dogma, but this is not a new concept. Bond’s work builds on an earlier breakthrough in treating congestive heart failure (CHF), in which case patients had been treated for decades with stimulant drugs to increase cardiac output. Beta blockers were prohibited because they initially further reduced the heart’s pumping power, but the stimulants ultimately caused the heart to wear out over time from the increased activity.

About a decade ago, the thinking on beta-blocker therapy was reversed when researchers discovered that although treatment with beta blockers reduced cardiac activity at first, the prognosis reversed itself after two to three months. This treatment shift reduced the mortality rate among CHF patients by up to 65 percent.

“Decades of conventional wisdom were overturned, and beta blockers replaced stimulants as the top drug for CHF patients,” Bond said. “For 30 years, intellect told us that beta blockers wouldn’t work to treat these patients, and unfortunately millions of heart patients died prematurely. It would be a tragedy to not have learned from that lesson.”

With his work based on this precedent, Bond points out that beta blockers are not the only example of paradoxical pharmacology. Hyperactive children are treated with the amphetamine-like Ritalin®, and the skin irritant retinoic acid is used to treat acne. Additionally, there has been research into using antipsychotic drugs traditionally used for schizophrenic patients to decrease the incidence of Alzheimer’s disease by suppressing the dopamine system, which is hypoactive in such neurodegenerative diseases. These examples further the case for investigating paradoxical approaches like Bond’s.

In Bond’s first clinical trial, he and his colleagues saw similar results in humans to what was seen in the mouse models. Mild asthmatics were treated for nine weeks with the beta blocker nadolol, with all subjects tolerating the drug and 80 percent experiencing a reduction in airway hyperresponsiveness. Laying the groundwork for continuing studies with beta blockers in the treatment of asthma, the results suggest there may be a way to counteract some of the negative aspects of traditional treatments.

“The principle that certain pharmacological compounds have different effects depending upon whether they are given for long or short periods has been demonstrated,” Bond said. “And even if I am correct about beta blockers ultimately being used in the treatment of asthma, there probably always will be a need for the inhaler-type agonist drugs to handle acute asthma attacks. I do believe, though, that beta blockers hold promise in a maintenance or preventative regimen that could reduce the number or severity of attacks and improve a patient’s quality of life.”

This research has received funding from the National Institutes of Health, as well as from two San Francisco-based organizations – a private biotechnology company called Inverseon and the philanthropic Sandler Program for Asthma Research. As the scientific founder of Inverseon, Bond leads a distinguished panel of scientists on the company’s advisory board, including Nobel Laureate in Medicine Sir James Black, who is considered the “father of beta blockers.”

“If we continue down this path, replicating these results, this paradoxical approach to asthma treatment may well become an important new approach to asthma therapy,” said Dr. William J. Garner, CEO of Inverseon. “We’ve already engaged in discussions with major pharmaceutical companies about taking this to the next level and are actively seeking additional funding for eventual product development.”

Source: University of Houston

Explore further: Liberia holds Senate vote amid Ebola fears

add to favorites email to friend print save as pdf

Related Stories

Microbial 'signature' for sexual crimes

2 hours ago

Bacterial communities living on an individual's pubic hairs could be used as a microbial 'signature' to trace their involvement in sexual assault cases, according to a study published in the open access journal Investigative Ge ...

Brazil: Google fined in Petrobras probe

3 hours ago

A Brazilian court says it has fined Google around $200,000 for refusing to intercept emails needed in a corruption investigation at state-run oil company Petrobras.

Atari's 'E.T.' game joins Smithsonian collection

3 hours ago

One of the "E.T." Atari game cartridges unearthed this year from a heap of garbage buried deep in the New Mexico desert has been added to the video game history collection at the Smithsonian.

Sony threatens to sue for publishing stolen emails

4 hours ago

A lawyer representing Sony Pictures Entertainment is warning news organizations not to publish details of company files leaked by hackers in one of the largest digital breaches ever against an American company.

Microsoft builds support over Ireland email case

4 hours ago

Microsoft said Monday it had secured broad support from a coalition of influential technology and media firms as it seeks to challenge a US ruling ordering it to hand over emails stored on a server in Ireland.

Recommended for you

Liberia holds Senate vote amid Ebola fears

4 hours ago

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate vote that has been criticized for its potential to spread the deadly Ebola disease.

Evidence-based recs issued for systemic care in psoriasis

Dec 19, 2014

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

Bacteria in caramel apples kills at least four in US

Dec 19, 2014

A listeria outbreak believed to originate from commercially packaged caramel apples has killed at least four people in the United States and sickened 28 people since November, officials said Friday.

Steroid-based treatment may answer needs of pediatric EoE patients

Dec 19, 2014

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal ...

Discovery of genes that predispose a severe form of COPD

Dec 19, 2014

A study by Ramcés Falfán-Valencia, researcher at the National Institute of Respiratory Diseases (INER), found that the mestizo Mexican population has a number of variations in certain genes that predispose ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.